Arkema rises after Q3 earnings beat, FY guidance confirmation

** Shares in Arkema AKE.PA are up 3.4%, on better-than-expected Q3 revenue, and 2026 outlook confirmation

** The French specialty chemicals maker reports sales for Q3 at €2.36 billion ($2.66 billion), ahead of the €2.27 bln consensus compiled by the company

** J.P.Morgan also notes a slight beat in Q3 adjusted EBITDA at €332 mln (+1% vs consensus), flagging results slightly better than the brokerage had forecast across all the key divisions in Specialty Materials

** The company maintains its 2026 outlook of a slightly higher year-on-year EBITDA at constant FX

** The broker says the guidance confirmation signals Arkema's ability to deliver a Q4 result better than normal seasonal patterns would imply, which "should be supportive for the shares"

** Including today's gains, the stock is up 14.7% year-to-date

($1 = 0.8880 euros)